Accessibility Tools

Medication Legend

℞: Medications that treat viral infections and tumors are marked with the "℞" symbol.
+: Medications that contain proteins for weight gain are marked with the "+" symbol.
++: Regenerative medications for neurogenesis are marked with the "++" symbol.

A new vaccine approved in the U.S. on Sept. 24 prevents both smallpox and the related disease monkeypox in adults. Marketed under the brand name JYNNEOS, the vaccine was developed by biotechnology firm Bavarian Nordic and tested by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

Current smallpox research focuses on developing vaccines, drugs and diagnostic tests to protect against the virus should it be used as an agent of bioterrorism. JYNNEOS was developed as an alternative to the current U.S. licensed smallpox vaccine, ACAM2000, which cannot be used by people with certain health conditions.

To assess the vaccine’s effectiveness, USAMRIID study director Phillip R. Pittman, M.D., led a clinical trial in collaboration with the U.S. Defense Health Agency (DHA). His team enrolled U.S. service members stationed in South Korea in the study, placing 440 participants into one of two groups. While the first group received two doses of JYNNEOS 28 days apart, the second group received a single dose of ACAM2000. Participants receiving JYNNEOS had a superior immune response and fewer side effects compared to those who received ACAM2000.

“In addition to its public health importance, this vaccine will have a direct impact on improving force health protection for U.S. troops who are required to be immunized against smallpox.”

Col. E. Darrin Cox, Commander of USAMRIID

While enhancing the medical readiness of U.S. fighting forces, the new smallpox vaccine also has been selected for inclusion in the Centers for Disease Control and Prevention’s (CDC) Strategic National Stockpile, the nation’s largest supply of potentially life-saving pharmaceuticals and medical supplies for use in a public health emergency.

Smallpox is an ancient disease that is highly contagious and often fatal in humans. Symptoms include fever, body aches, and a skin rash that develops into fluid-filled lesions. The smallpox virus is spread through saliva and droplets from the respiratory tract, or by direct or indirect contact with the virus as it is shed from skin lesions. The virus also can be spread through other body fluids and contaminated clothing or bedding.

Monkeypox is a rare disease that does not occur naturally in the U.S. It begins with fever, headache, muscle aches and exhaustion and is typically milder than smallpox, though it can be fatal in some cases. Monkeypox is transmitted to people from wild animals, such as rodents and primates. In 2003, the U.S. experienced an outbreak of monkeypox, which was the first time human monkeypox was reported outside of Africa.

Content Original Link:

https://globalbiodefense.com/2019/10/20/army-study-leads-to-approval-of-new-smallpox-vaccine/

Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.

VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.